The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease

Expert Review of Clinical Immunology

Volumn 11, Issue 7, 2015, Pages 819-825

  Burns, Jane C ^a   Franco, Alessandra ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

acquired heart disease; coronary artery aneurysms; immune regulation; Kawasaki disease; myocardial infarction; pediatric vasculitis

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CYTOKINE ANTIBODY; EPITOPE; FC RECEPTOR; IMMUNOGLOBULIN; INTERLEUKIN 10; NEUTRALIZING ANTIBODY; IL10 PROTEIN, HUMAN;

ANTIBODY SPECIFICITY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTICENTER STUDY (TOPIC); RECOGNITION; REGULATORY T LYMPHOCYTE; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERLEUKIN-10; MUCOCUTANEOUS LYMPH NODE SYNDROME; RECEPTORS, IGG; T-LYMPHOCYTES, REGULATORY;

EID: 84932083702     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1044980     Document Type: Review

References (60)

1. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment and long term management of kawaski disease: a statement for helath professionals from the committee for rheumatic fever, endocarditis and kawaski disease, council on cardiovascular diseases in the young, american heart association. Circulation 2004;110:2747-71
2. Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54(3):271-6
3. Burns JC, Shike H, Gordon JB, et al. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996;28:253-7
4. Imbach P, Barandun S, d'Apuzzo V. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-31
5. Furusho K, Sato K, Soeda T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1983;2(8363):1359
6. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315(6):341-7 Randomized, open-label study of intravenous immunoglobulin (IVIG) plus aspirin versus aspirin alone that established IVIG as an effective therapy for Kawasaki disease (KD). At 2 weeks after enrollment, coronary artery abnormalities were present in 18 of 78 children (23%) in the aspirin alone group, as compared with 6 of 75 (8%) in the IVIG group (p = 0.01).
7. Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96(6):1057-61 Important meta-analysis that helped to settle the debate about optimal dose of IVIG in KD and suggested a dose-response threshold.
8. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324(23):1633-9
9. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345(10):747-55
10. Tha-In T, Bayry J, Metselaar HJ, et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008;29(12):608-15
11. Nagelkerke S, Dekkers G, Kustiawan I, et al. Inhibition of FcgR-mediated phagocytosis by IVIG is independent of IgG-Fc sialylation and FcgRIIb in human macrophages. Blood 2014;124:3709-18
12. Anthony RM, Kobayashi T, Wermeling F, et al. Intravenous gammaglobulin suppresses inflammation through a novel T(H) 2 pathway. Nature 2011;475(7354):110-13
13. Khor CC, Davila S, Breunis WB, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Gen 2011;43(12):1241-6
14. Duan J, Lou J, Zhang Q, et al. A genetic variant rs1801274 in FCGR2A as a potential risk marker for kawasaki disease: A case-control study and meta-analysis. PLoS One 2014;9(8):e103329
15. Shrestha S, Wiener H, Shendre A, et al. Role of activating FcgammaR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response. Circ Cardiovasc Genet 2012;5(3):309-16
16. Shrestha S, Wiener HW, Olson AK, et al. Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease. J Allergy Clin Immunol 2011;128(3):677-80
17. Shendre A, Wiener HW, Zhi D, et al. High-density genotyping of immune loci in Kawasaki disease and IVIG treatment response in European-American case-parent trio study. Genes Immun 2014;15(8):534-42
18. Onouchi Y, Ozaki K, Burns JC, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Gen 2012;44(5):517-21
19. Abe J, Jibiki T, Noma S, et al. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 2005;174(9):5837-45 Microarray paper that outlines changes in transcript abundance patterns in response to IVIG in KD patients. Provides a good catalog of gene expression changes over time in response to IVIG.
20. Trinath J, Hegde P, Sharma M, et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 2013;122(8):1419-27
21. Burns JC, Song Y, Bujold M, et al. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. Clin Exp Immunol 2013;174(3):337-44
22. Ephrem A, Chamat S, Miquel C, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008;1151(2):715-22
23. Maddur MS, Vani J, Hegde P, et al. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol 2011;127(3):823-30
24. Franco A, Touma R, Song Y, et al. Specificity of regulatory T cells that modulate vascular inflammation. Autoimmunity 2014;47:95-104 Describes one mechanism by which IVIG might modulate inflammation in acute KD through expansion of Fc-specific natural regulatory T cells that expand and secrete IL-10 following IVIG infusion. Experiments have implications beyond KD and describe a new story in T cell/B cell cooperation.
25. von Gunten S, Schaub A, Vogel M, et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 2006;108(13):4255-9
26. Finberg RW, Newburger JW, Mikati MA, et al. Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood. J Pediatr 1992;120(3):376-80
27. Franco A, Shimizu C, Tremoulet AH, et al. Memory T cells and characterization of peripheral T cell clones in acute Kawasaki disease. Autoimmunity 2010;43:317-24
28. Shimizu C, Oharaseiki T, Takahashi K, et al. The role of TGF-b and myofibroblasts in the arteritis of Kawasaki disease. Hum Pathol 2012;44:189-98
29. Makoto M, Yoshioka Y, Kitoh A, et al. Functional delination and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911
30. Feuerer M, Hill JA, Mathis D, et al. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 2010;10:698-5
31. Jordan MS, Boesteanu A, Reed AJ, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001;2:301-6
32. Miyara M, Yoshioka Y, Kito A, et al. Functional delineation and differentiation dinamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911
33. Chen WJ, Jin W, Hardegen N, et al. Conversion of Peripheral CD4+CD25-Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3. J Exp Med 2003;198:1875-86
34. Kretschmer K, Apostolou I, Hawiger D, et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nature Immunol 2005;6:1-9
35. Apostolou I, Sarukhan A, Klein L, et al. Origin of regulatory T cells with known specificity for antigen. Nat Immunol 2002;3:756-63
36. Apostolou I, von Boemer H. In vivo instruction od suppressor committment in naive T cells. J Experimental Med 2004;199:1401-8
37. Rivino L, Gruarin P, Häringer B, et al. CCR6 is expressed on IL-10 producing, autoreactive memory T cell population with context-dependent regulatory function. J Exp Med 2010;207:565-77
38. Roncarolo MG, Battaglia M. Regulatory T cell immunotherapy for tolerance to self antigens and to alloantigens in humans. Nat Rev 2007;7:585-98
39. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010;11:7-13
40. von Boehmer H, Melchers F. Checkpoints in lymphocytes development and autoimmune disease. Nat Immunol 2010;11:14-20
41. Kassiotis G, O'Garra A. Immunology. Immunity benefits from a little suppression. Science 2008;320:1168-9
42. O'Garra A, Vieira PL, Vieira P, et al. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest 2004;114:1372-8
43. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10:170-81
44. Hsu CH, Chen MR, Hwang FY, et al. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome. Pediatr Infect Dis J 1993;12(6):509-12
45. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta paediatrica Japonica 1991;33(6):805-10
46. Burns JC, Touma R, Song Y, et al. Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease. Autoimmunity 2015:1-8 In vitro experiments with patient cells define discrete immunodominant regions within the Fc protein that expand a subset of natural regulatory T cells. Epitope-specific regulatory T cell responses were documented in KD patients who failed to respond to the whole Fc protein after IVIG. Suggests that antigen processing or presentation may define KD patients who develop aneurysms.
47. Sundel RP, Burns JC, Baker A, et al. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123(4):657-9
48. Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008;153(6):833-8
49. Zhu BH, Lv HT, Sun L, et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr 2012;171(3):571-8
50. Tremoulet AH, Pancoast P, Franco A, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2012;161(3):506-512 e501
51. Cohen S, Tacke CE, Straver B, et al. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. Ann Rheum Dis 2012;71(12):2059-61
52. Hokosaki T, Mori M, Nishizawa T, et al. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr Int 2012;54(1):99-103
53. Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011;158(4):644-649 e641
54. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012;379(9826):1613-20
55. Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011;158(5):831-835 e833
56. Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008;153(1):117-21
57. Dominguez SR, Anderson MS, El-Adawy M, Glode MP. Preventing coronary artery abnormalities: a need for earlier diagnosis and treatment of kawasaki disease. Pediatr Infect Dis J 2012;31(12):1217-20
58. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007;356(7):663-75
59. Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 2014;383(9930):1731-8
60. Ogata S, Shimizu C, Franco A, et al. Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin g. PLoS ONE 2013;8(12):e81448